Lilly adds to immune drug pipeline with $2.9B Merida buyout
BioPharma Dive
The big drugmaker s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.
pharminent
August 31, 2026 (Last updated: September 1, 2026)
BioPharma Dive
The big drugmaker s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.
